These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20175784)

  • 1. Viral shedding after p53 adenoviral gene therapy in 10 cases of esophageal cancer.
    Kawahira H; Matsushita K; Shiratori T; Shimizu T; Nabeya Y; Hayashi H; Ochiai T; Matsubara H; Shimada H
    Cancer Sci; 2010 Jan; 101(1):289-91. PubMed ID: 20175784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
    Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
    Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
    Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
    Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors.
    Heideman DA; Snijders PJ; Craanen ME; Bloemena E; Meijer CJ; Meuwissen SG; van Beusechem VW; Pinedo HM; Curiel DT; Haisma HJ; Gerritsen WR
    Cancer Gene Ther; 2001 May; 8(5):342-51. PubMed ID: 11477454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens.
    Wang F; Patel DK; Antonello JM; Washabaugh MW; Kaslow DC; Shiver JW; Chirmule N
    Hum Gene Ther; 2003 Jan; 14(1):25-36. PubMed ID: 12573056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens.
    Buskens CJ; Marsman WA; Wesseling JG; Offerhaus GJ; Yamamoto M; Curiel DT; Bosma PJ; van Lanschot JJ
    Ann Surg; 2003 Dec; 238(6):815-24; discussion 825-6. PubMed ID: 14631218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical study of adenoviral p53 gene therapy for esophageal cancer.
    Shimada H; Shimizu T; Ochiai T; Liu TL; Sashiyama H; Nakamura A; Matsubara H; Gunji Y; Kobayashi S; Tagawa M; Sakiyama S; Hiwasa T
    Surg Today; 2001; 31(7):597-604. PubMed ID: 11495154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection.
    Drazan KE; Shen XD; Csete ME; Zhang WW; Roth JA; Busuttil RW; Shaked A
    Surgery; 1994 Aug; 116(2):197-203; discussion 203-4. PubMed ID: 8047986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland.
    Zheng C; Nikolov NP; Alevizos I; Cotrim AP; Liu S; McCullagh L; Chiorini JA; Illei GG; Baum BJ
    J Gene Med; 2010 Jan; 12(1):3-10. PubMed ID: 19941317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours.
    Habib NA; Hodgson HJ; Lemoine N; Pignatelli M
    Hum Gene Ther; 1999 Aug; 10(12):2019-34. PubMed ID: 10466636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of human papillomavirus DNA and p53 gene mutations in esophageal cancer samples and adjacent normal mucosa.
    Astori G; Merluzzi S; Arzese A; Brosolo P; de Pretis G; Maieron R; Pipan C; Botta GA
    Digestion; 2001; 64(1):9-14. PubMed ID: 11549832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for esophageal squamous cell carcinoma.
    Shimada H; Ochiai T
    Front Biosci; 2008 May; 13():3364-72. PubMed ID: 18508438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.
    Griscelli F; Opolon P; Saulnier P; Mami-Chouaib F; Gautier E; Echchakir H; Angevin E; Le Chevalier T; Bataille V; Squiban P; Tursz T; Escudier B
    Gene Ther; 2003 Mar; 10(5):386-95. PubMed ID: 12601393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo.
    Marsman WA; Buskens CJ; Wesseling JG; Offerhaus GJ; Bergman JJ; Tytgat GN; van Lanschot JJ; Bosma PJ
    Cancer Gene Ther; 2004 Apr; 11(4):289-96. PubMed ID: 14765131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells.
    Shimada H; Liu TL; Ochiai T; Shimizu T; Haupt Y; Hamada H; Abe T; Oka M; Takiguchi M; Hiwasa T
    Oncogene; 2002 Feb; 21(8):1208-16. PubMed ID: 11850840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an adenoviral vector that expresses the canine p53 gene on cell growth of canine osteosarcoma and mammary adenocarcinoma cell lines.
    Yazawa M; Setoguchi A; Hong SH; Uyama R; Nakagawa T; Kanaya N; Nishimura R; Sasaki N; Masuda K; Ohno K; Tsujimoto H
    Am J Vet Res; 2003 Jul; 64(7):880-8. PubMed ID: 12856773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.
    Gabrilovich DI
    Expert Opin Biol Ther; 2006 Aug; 6(8):823-32. PubMed ID: 16856803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.